Rilpivirine-induced anti-inflammatory effects in non-alcoholic fatty liver disease involve the inhibition of CCL2/CCR2 axis
Por:
Moragrega, A, Gruevska, A, Fuster-Martinez, I, Benedicto, A, Lucantoni, F, Esplugues, J, Apostolova, N and Blas-Garcia, A
Publicada:
1 jul 2021
Categoría:
Hepatology
Resumen:
Filiaciones:
:
Univ Valencia, Farmacol, Valencia, Spain
FISABIO Fdn Fomento Invest Sanitaria & Biomed Com, Valencia, Spain
:
Univ Valencia, Farmacol, Valencia, Spain
FISABIO Fdn Fomento Invest Sanitaria & Biomed Com, Valencia, Spain
Fuster-Martinez, I:
Univ Valencia, Farmacol, Valencia, Spain
FISABIO Fdn Fomento Invest Sanitaria & Biomed Com, Valencia, Spain
:
Univ Valencia, Farmacol, Valencia, Spain
FISABIO Fdn Fomento Invest Sanitaria & Biomed Com, Valencia, Spain
:
Univ Valencia, Farmacol, Valencia, Spain
FISABIO Fdn Fomento Invest Sanitaria & Biomed Com, Valencia, Spain
:
Univ Valencia, Farmacol, Valencia, Spain
FISABIO Fdn Fomento Invest Sanitaria & Biomed Com, Valencia, Spain
CIBERehd Ctr Invest Biomed Red Enfermedades Hepat, Valencia, Spain
:
Univ Valencia, Farmacol, Valencia, Spain
FISABIO Fdn Fomento Invest Sanitaria & Biomed Com, Valencia, Spain
CIBERehd Ctr Invest Biomed Red Enfermedades Hepat, Valencia, Spain
:
FISABIO Fdn Fomento Invest Sanitaria & Biomed Com, Valencia, Spain
CIBERehd Ctr Invest Biomed Red Enfermedades Hepat, Valencia, Spain
Univ Valencia, Fisiol, Valencia, Spain
|